Keebeck Wealth Management Makes New Investment in TransMedics Group, Inc. $TMDX

Keebeck Wealth Management acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 5,820 shares of the company’s stock, valued at approximately $387,000.

A number of other institutional investors have also recently made changes to their positions in TMDX. Hussman Strategic Advisors Inc. purchased a new stake in shares of TransMedics Group in the fourth quarter worth about $1,788,000. Candriam S.C.A. grew its holdings in TransMedics Group by 45.4% during the 1st quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock valued at $15,783,000 after buying an additional 49,580 shares in the last quarter. M&T Bank Corp grew its holdings in TransMedics Group by 749.2% during the 4th quarter. M&T Bank Corp now owns 18,572 shares of the company’s stock valued at $2,259,000 after buying an additional 16,385 shares in the last quarter. Regency Capital Management Inc. DE bought a new stake in TransMedics Group in the 1st quarter worth approximately $2,172,000. Finally, Geneos Wealth Management Inc. bought a new stake in TransMedics Group in the 1st quarter worth approximately $3,045,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TMDX. Canaccord Genuity Group reaffirmed a “buy” rating and set a $124.00 price objective on shares of TransMedics Group in a report on Tuesday, June 30th. Weiss Ratings lowered shares of TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, July 28th. Oppenheimer cut shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $124.18.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

TransMedics Group Stock Up 4.3%

Shares of NASDAQ:TMDX opened at $94.77 on Friday. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The business has a 50 day simple moving average of $77.49 and a two-hundred day simple moving average of $95.32. The firm has a market capitalization of $3.28 billion, a PE ratio of 24.36 and a beta of 1.90. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The business had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same quarter in the previous year, the company posted $0.92 earnings per share. The company’s quarterly revenue was up 20.7% compared to the same quarter last year. On average, equities analysts predict that TransMedics Group, Inc. will post 1.47 EPS for the current year.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.